科前生物
(688526)
| 流通市值：70.29亿 | | | 总市值：70.29亿 |
| 流通股本：4.66亿 | | | 总股本：4.66亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 398,150,650.98 | 688,952,391.95 | 800,292,120.31 | 581,740,744.51 |
| 应收票据及应收账款 | 334,409,367.7 | 297,759,485.57 | 312,354,129.45 | 331,412,360.97 |
| 应收账款 | 334,409,367.7 | 297,759,485.57 | 312,354,129.45 | 331,412,360.97 |
| 应收款项融资 | 610 | 5,276,435.29 | 10 | 11,736,295.65 |
| 预付款项 | 4,340,687.65 | 3,828,620.39 | 3,690,384.25 | 7,690,320.37 |
| 其他应收款合计 | 4,822,722 | 4,902,108.85 | 3,892,107.21 | 3,728,772 |
| 存货 | 110,569,040.67 | 133,639,615.85 | 146,435,411.57 | 144,801,907.79 |
| 一年内到期的非流动资产 | 804,681,617.19 | 753,584,688.82 | 484,148,243.7 | 468,740,473.53 |
| 其他流动资产 | 71,949,048.43 | 38,085,602.46 | 26,846,425.51 | 271,195,549.53 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 2,396,570,097.09 | 2,571,347,456.93 | 2,472,776,254.39 | 2,566,086,573.76 |
| 非流动资产: | | | | |
| 其他权益工具投资 | 94,020,581.59 | 100,941,818.06 | 99,893,725.04 | 96,571,787.33 |
| 固定资产 | 736,142,700.86 | 755,649,505.04 | 775,940,117.7 | 799,006,067.68 |
| 在建工程 | 107,621,473.96 | 74,703,106.42 | 53,057,251.88 | 43,051,020.11 |
| 生产性生物资产 | 8,701,870.98 | 7,513,017.09 | 8,774,993.59 | 10,049,956.19 |
| 使用权资产 | 6,028,025.81 | 6,332,438.27 | 6,605,147.72 | 6,790,469.7 |
| 无形资产 | 59,567,614.02 | 57,662,071.09 | 58,521,528.16 | 60,028,728.9 |
| 商誉 | 3,307,452.36 | 3,307,452.36 | 3,307,452.36 | 3,307,452.36 |
| 长期待摊费用 | 1,212,679.99 | 1,037,503.32 | 1,107,993.33 | 1,178,483.34 |
| 递延所得税资产 | 189,357.67 | 246,869.57 | 505,197.92 | 299,894.73 |
| 其他非流动资产 | 1,018,602,996.42 | 892,114,739.42 | 1,137,894,416.58 | 1,084,879,036.91 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 2,035,394,753.66 | 1,899,508,520.64 | 2,145,607,824.28 | 2,105,162,897.25 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 4,431,964,850.75 | 4,470,855,977.57 | 4,618,384,078.67 | 4,671,249,471.01 |
| 流动负债: | | | | |
| 短期借款 | 57,038,838.8 | 202,132,835.36 | 155,080,327.87 | 206,650,359.95 |
| 应付票据及应付账款 | 135,178,858.53 | 123,551,368.06 | 120,825,592.32 | 165,029,720.01 |
| 其中：应付票据 | 18,505,225.55 | 17,475,562.5 | 17,062,000 | 32,693,495.9 |
| 应付账款 | 116,673,632.98 | 106,075,805.56 | 103,763,592.32 | 132,336,224.11 |
| 合同负债 | 179,480,006.86 | 172,483,564.7 | 203,846,267.32 | 157,606,070.48 |
| 应付职工薪酬 | 41,058,984.46 | 30,673,279.39 | 20,590,251.39 | 49,568,986.38 |
| 应交税费 | 29,078,160.5 | 21,231,229.72 | 63,175,411.27 | 57,815,317.67 |
| 其他应付款合计 | 40,744,259.08 | 37,974,051.54 | 40,301,728.7 | 39,636,442.51 |
| 一年内到期的非流动负债 | 1,240,113.35 | 31,210,100.44 | 31,175,720.11 | 81,113,415.88 |
| 其他流动负债 | 1,460,766.89 | 1,173,975 | 2,314,373.57 | 831,754.02 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 485,279,988.47 | 620,430,404.21 | 637,309,672.55 | 758,252,066.9 |
| 非流动负债: | | | | |
| 租赁负债 | 5,442,532.35 | 5,421,680.86 | 5,674,933.8 | 5,745,129.78 |
| 递延收益 | 67,507,699.7 | 69,380,611.94 | 56,708,119.75 | 56,624,538.73 |
| 递延所得税负债 | 15,062,730.22 | 11,176,905.99 | 15,012,338.28 | 12,970,411.87 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 88,012,962.27 | 85,979,198.79 | 77,395,391.83 | 75,340,080.38 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 573,292,950.74 | 706,409,603 | 714,705,064.38 | 833,592,147.28 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 466,128,056 | 466,168,016 | 466,168,016 | 466,168,016 |
| 资本公积 | 1,140,131,360.65 | 1,140,618,473.05 | 1,140,618,473.05 | 1,140,618,473.05 |
| 减:库存股 | 31,670,006.58 | 30,582,266.52 | 24,950,912.37 | 574,624.8 |
| 其他综合收益 | 17,778,531.02 | 29,709,492.24 | 28,655,920.39 | 25,333,622.92 |
| 盈余公积 | 269,372,446.08 | 269,372,446.08 | 269,372,446.08 | 269,372,446.08 |
| 未分配利润 | 1,995,494,857.19 | 1,887,502,506.32 | 2,021,937,660.08 | 1,934,709,264.3 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 3,857,235,244.36 | 3,762,788,667.17 | 3,901,801,603.23 | 3,835,627,197.55 |
| 少数股东权益 | 1,436,655.65 | 1,657,707.4 | 1,877,411.06 | 2,030,126.18 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 3,858,671,900.01 | 3,764,446,374.57 | 3,903,679,014.29 | 3,837,657,323.73 |
| 负债和股东权益合计 | 4,431,964,850.75 | 4,470,855,977.57 | 4,618,384,078.67 | 4,671,249,471.01 |
| 公告日期 | 2024-10-31 | 2024-08-30 | 2024-04-30 | 2024-04-02 |
| 审计意见(境内) | | | | 标准无保留意见 |